TGFB1 and liver disorder: Previous studies in mouse models of liver fibrosis showed that a neutralising antibody blocking GDF‐15 reduces hepatic stellate cell activation via TGF‐β‐signalling [37], a key profibrogenic pathway in liver disease [38].